Surgeons at the Ohio State University Medical Center have performed the first incisionless surgery in the US for gastroesophageal reflux disease (GERD) using a device known EsophyX. The Food and Drug Administration have approved the device for correcting GERD also known as heartburn.
The surgeons have treated the first two patients in the country by using the device.
Reflux Esophagitis
Reflux esophagitis is a condition causing inflammation of the lining of the esophagus. This happens when there is a upward movement of the acid from the stomach due to weakness of the esophageal sphincter.
Advertisement
The mechanism, which is new in the US, has been proven safe and effective in patients treated throughout Europe for GERD.
According to the surgeons, the new procedure does not leave any scars and results in minimal post-operative pain. It also reduces patients' recovery time significantly, they say.
"The medical device offers a treatment for patients who suffer from an advanced degree of GERD and, until now, would have been candidates for surgery," said Dr. Scott Melvin, division director, general and gastrointestinal surgery, and director, Center for Minimally Invasive Surgery at the OSU Medical Center.
Heartburn, known to be linked with an increased risk of cancer of the oesophagus, is a condition in which acid refluxes from the stomach into the oesophagus, and causes burning sensation in the chest.
The incisionless surgery allows reconstruction of the one-way valve at the top of the stomach, when the valve is defective. During the procedure, the new tubular device is introduced to the body totally through the mouth, and is then advanced down the oesophagus into the stomach.
A small fiberoptic camera located within the device keeps surgeons informed about the progress of the operation.
"Throughout medical history, we have gone from a very painful surgery, to a better tolerated surgery and, now, to a potentially pain-free incisionless procedure. In addition, the new procedure allows a treatment option for many patients when reflux is not severe enough to require surgery," said Melvin.
"We are far from incisionless technology's adoption for widespread use with other diseases, but there is a lot of discussion among surgeons about these new techniques. Our use of this type of technology will continue to allow us to treat many diseases with minimal pain from surgery," added Melvin.
Source: ANI
GAN/V
Advertisement
"The medical device offers a treatment for patients who suffer from an advanced degree of GERD and, until now, would have been candidates for surgery," said Dr. Scott Melvin, division director, general and gastrointestinal surgery, and director, Center for Minimally Invasive Surgery at the OSU Medical Center.
Heartburn, known to be linked with an increased risk of cancer of the oesophagus, is a condition in which acid refluxes from the stomach into the oesophagus, and causes burning sensation in the chest.
The incisionless surgery allows reconstruction of the one-way valve at the top of the stomach, when the valve is defective. During the procedure, the new tubular device is introduced to the body totally through the mouth, and is then advanced down the oesophagus into the stomach.
A small fiberoptic camera located within the device keeps surgeons informed about the progress of the operation.
"Throughout medical history, we have gone from a very painful surgery, to a better tolerated surgery and, now, to a potentially pain-free incisionless procedure. In addition, the new procedure allows a treatment option for many patients when reflux is not severe enough to require surgery," said Melvin.
"We are far from incisionless technology's adoption for widespread use with other diseases, but there is a lot of discussion among surgeons about these new techniques. Our use of this type of technology will continue to allow us to treat many diseases with minimal pain from surgery," added Melvin.
Source: ANI
GAN/V
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News
Cerebrospinal fluid (CSF) leaks are detected in approximately 1-3% of adults who have experienced a traumatic brain injury.
The optogenetic activation of hippocampal astrocytes can be viewed as a novel therapeutic avenue for addressing Alzheimer's disease.
In Alzheimer's disease condition, the control and adjustment of ABCA7 levels in response to inflammation and the decrease in the availability of cholesterol.
Atopic dermatitis (AD) and inflammatory bowel disease (IBD) can lead to alterations in the microbiome, and disruptions in the skin and gut barrier.
Gaining insights into mortality risks among vitiligo patients will enhance patient counseling, healthcare monitoring, and overall patient management strategies.
